1. Home
  2. PFX vs MXCT Comparison

PFX vs MXCT Comparison

Compare PFX & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PFX

PhenixFIN Corporation

N/A

Current Price

$42.01

Market Cap

85.5M

Sector

Finance

ML Signal

N/A

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.23

Market Cap

93.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFX
MXCT
Founded
2010
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.5M
93.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PFX
MXCT
Price
$42.01
$1.23
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$5.50
AVG Volume (30 Days)
3.6K
1.2M
Earning Date
05-08-2026
05-12-2026
Dividend Yield
3.57%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.30
$0.64
52 Week High
$53.59
$2.40

Technical Indicators

Market Signals
Indicator
PFX
MXCT
Relative Strength Index (RSI) 52.05 72.82
Support Level $38.82 $0.72
Resistance Level $42.54 $1.75
Average True Range (ATR) 0.75 0.09
MACD 0.36 0.02
Stochastic Oscillator 54.73 91.77

Price Performance

Historical Comparison
PFX
MXCT

About PFX PhenixFIN Corporation

PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: